Table 1 Studies with cytotoxic chemotherapy alone or in combination with biologic agents
From: Systemic therapy for recurrent or metastatic salivary gland malignancies
Author (year) | Regimen | No of patients | Histology | Progression required | ORR | CBR | Median OS (months) |
|---|---|---|---|---|---|---|---|
Airoldi et al. [6] | Vino vs Cis + Vino | 20 vs 16 | Ad (9), ACC (22), MEC (1), others (4) | Yes | 20 % vs 44 % | 65 % vs 81 % | 8.5 vs 10 |
Gedlicka et al. [7] | Mitoxantrone + Cis | 14 | NR | No | 14 % | 79 % | 27 |
Gilbert et al. [11] | Paclitaxel | 45 | Ad (17), ACC (14), MEC (14) | No | 18Â % | 51Â % | 12.5 |
van Herpen et al.[12] | Gemcitabine | 21 | ACC (21) | No | 0Â % | 52Â % | NR |
Ross et al. [10] | Epirubicin + Plat + 5FU | 8 | ACC (8) | No | 12 % | 75 % | 27 |
Laurie et al. [8] | Plat + Gemcitabine | 33 | Ad (8), ACC (10), MEC (4), others (11) | Yesa | 24 % | 82 % | 13.8 |
Ghosal et al. [47] | Cis + Imatinib | 28 | ACC (28) | No | 11 % | 79 % | 35 |
Argiris et al. [50] | Bor → Bor + Dox | 24 | ACC (24) | Yes | 0 % and 8 %b | 63 % and 58%b | 21 |
Hitre et al. [49] | Cetuximab + Cis + 5FU | 12 | ACC (12) | No | 42 % | 92 % | 24 |
Airoldi et al. [9] | Cis + Vino | 60 | Ad (15), ACC (34) | Yes | 23 % | 57 % | 10c |